GURUFOCUS.COM » STOCK LIST » Basic Materials » Chemicals » Balchem Corp (STU:BL9B) » Definitions » Research & Development

Balchem (STU:BL9B) Research & Development : €16.1 Mil (TTM As of Mar. 2025)


View and export this data going back to 1986. Start your Free Trial

What is Balchem Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Balchem's Research & Development for the three months ended in Mar. 2025 was €4.3 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2025 was €16.1 Mil.

Balchem Research & Development Historical Data

The historical data trend for Balchem's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Balchem Research & Development Chart

Balchem Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.49 11.97 11.51 13.80 16.04

Balchem Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.77 3.58 3.90 4.31 4.31

Balchem Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €16.1 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Balchem  (STU:BL9B) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Balchem Research & Development Related Terms

Thank you for viewing the detailed overview of Balchem's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Balchem Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Basic Materials » Chemicals » Balchem Corp (STU:BL9B) » Definitions » Research & Development
Comparable Companies
ESI NEU CBT SXT ALB AXTA AVNT WDFC FUL HWKN LIN XPAR:AI SHW ECL APD XSWX:GIVN ISX:TPIA XSWX:SIKA OCSE:NSIS B XAMS:DSFIR
Traded in Other Exchanges
BCPC:USA BL9B:Germany
Address
5 Paragon Drive, Montvale, NJ, USA, 07645
Website
https://www.balchem.com
Balchem Corp is engaged in the development, manufacture, and marketing of specialty performance ingredients and products for various industries. The company's reportable segments are; Human Nutrition and Health, which generates maximum revenue, and provides human-grade choline nutrients and mineral amino acid chelated products through this segment for nutrition and health applications; Animal Nutrition and Health, which provides nutritional products derived from its microencapsulation and chelation technologies in addition to the essential nutrient choline chloride; and the Specialty Products segment includes re-packaging and distributing several performance gases and chemicals. Geographically, the company derives its key revenue from the United States and the rest from foreign countries.

Balchem Headlines

No Headlines